Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466409 | 0.93 | PTGDR2 (0.56) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL1921782 | 0.90 | PTGDR2 (0.57) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL1467977 | 0.89 | PTGDR2 (0.62) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL1465815 | 0.86 | PTGDR2 (0.50) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL1599312 | 0.86 | PTGDR2 (0.56) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL1466412 | 0.85 | PTGDR2 (0.51) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL3723720 | 0.84 | PTGDR2 (0.52) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL3792480 | 0.84 | PTGDR2 (0.52) | PTGDR2PTGDRPTGIRCYP2C9 | |
| SCHEMBL1465979 | 0.83 | PTGDR2 (0.46) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL1422452 | 0.83 | PTGDR2 (0.52) | PTGDR2PTGDRPTGIRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LTD (GB) | 2015-09-03 | — | — | US | disclosed |
| US-8980927-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8563536-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2250161-B1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | ATOPIX THERAPEUTICS LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20110123547-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-7919512-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-20100266535-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-7750027-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 214/4885PTGDR 386/4885PTGIR 1320/4885 |
| US-20100266535-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 214/4885PTGDR 386/4885PTGIR 1320/4885 |
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 218/4885PTGDR 386/4885PTGIR 1323/4885 |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, HRH4 | PTGDR2 233/4885PTGDR 394/4885PTGIR 1326/4885 |
| US-20110123547-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | PTGDR2 214/4885PTGDR 386/4885PTGIR 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.